Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Momenta Pharmaceuticals has reported revenues of $51.96m for the third quarter ended 30 September 2010, compared to $4m for the same period in 2009.
Subscribe to our email newsletter
The increase in revenue was due to $44.2m of profit share earned from commercial sales of Enoxaparin sodium injection and the $5m regulatory milestone earned upon FDA marketing approval of eEnoxaparin sodium injection in July of 2010.
Momenta has posted a net income of $32.12m for the third quarter 2010, or $0.70 per diluted share, compared to net loss of $14.65m, or $0.38 loss per diluted share, for the comparable period in 2009.
Momenta’s operating income was $32.15m, compared to operating loss of $14.54m for the comparable period in 2009.
For the nine months ended 30 September 2010, revenue was $58.45m, compared to $14.6m for the year ago period.
Operating income was $1.17m for the nine months ended 30 September 2010, compared to $49.52m for the year ago period.
Net loss was $1.03m, or $0.02 per diluted share, compared to $49.32m, or $1.27 loss per diluted share, for the year ago period.